Intellia Therapeutics (NTLA) Announces Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) posted its quarterly earnings data on Wednesday. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16), reports. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.31) earnings per share.

Intellia Therapeutics (NTLA) opened at $32.43 on Wednesday. Intellia Therapeutics has a one year low of $11.15 and a one year high of $35.99. The stock has a market cap of $1,200.21, a PE ratio of -21.29 and a beta of 2.42.

In other news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 12.80% of the company’s stock.

An institutional investor recently raised its position in Intellia Therapeutics stock. State Street Corp boosted its stake in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 52.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 164,798 shares of the company’s stock after buying an additional 56,363 shares during the quarter. State Street Corp owned 0.46% of Intellia Therapeutics worth $2,638,000 as of its most recent filing with the Securities and Exchange Commission. 68.14% of the stock is currently owned by institutional investors.

NTLA has been the topic of a number of recent research reports. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, December 12th. TheStreet lowered shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, December 14th. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. ValuEngine lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, JMP Securities initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $33.00.

COPYRIGHT VIOLATION NOTICE: This report was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply